4/A: Processa Director Corrects Stock Ownership Filing
Insider Transaction Amendment
Processa Pharmaceuticals Director Geraldine Pannu filed an amended Form 4 to correct previously reported beneficial ownership of company stock.
Summary
- Geraldine Pannu, a Director of Processa Pharmaceuticals, Inc., filed an amended Form 4 (Form 4/A).
- The amendment corrects the number of beneficially owned shares previously reported on a Form 4 filed on September 18, 2024.
- The original Form 4, which contained an error, is now retracted by this amendment.
- The filing reports the acquisition of 31,206 restricted stock units at a price of $0.
- These restricted stock units vest on the earlier of June 28, 2025, or the next annual meeting of stockholders, subject to certain distribution requirements.
- Following the corrected transaction, Geraldine Pannu beneficially owns a total of 36,275 shares of Processa Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The filing is a procedural correction of previously reported beneficial ownership, not indicating positive or negative operational or financial performance.
Positives
- Ensures accurate public disclosure of insider beneficial ownership, enhancing transparency for investors.
Negatives
- The initial error in reporting beneficial ownership indicates an administrative oversight in prior filings.
Future Outlook
No forward-looking statements or guidance are provided in this filing beyond the vesting schedule of the restricted stock.
Management Comments
- "Amending to correct the beneficially owned shares reported on the Form 4 filed September 18, 2024."
- "Amendment filed to retract the prior Form 4, which was filed in error."
Industry Context
This filing is a routine insider transaction amendment and does not provide information relevant to broader industry trends or competitor analysis.
Comparison to Industry Standards
- Not applicable as this filing is a procedural correction of insider beneficial ownership and does not contain performance metrics or project details for industry comparison.
Stakeholder Impact
- Provides accurate and updated information on director share ownership to shareholders.
Next Steps
- The restricted stock units are scheduled to vest on the earlier of June 28, 2025, or the next annual meeting of stockholders.
Key Dates
| Date | Description |
|---|---|
| 09/03/2024 | Date the restricted stock became exercisable. |
| 09/18/2024 | Date of the original Form 4 filing that contained an error and is being corrected. |
| 06/28/2025 | Earliest vesting date for the restricted stock. |
| 07/24/2025 | Date of the earliest transaction reported (acquisition of restricted stock). |
| 07/28/2025 | Date the original amendment (Form 4/A) was filed, which this current filing further amends. |
| 09/18/2025 | Date this current amended Form 4/A was signed by the reporting person. |
Keywords
Processa Pharmaceuticals, PCSA, Geraldine Pannu, Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.